WordNet

cowardly or treacherous; "the little yellow stain of treason"-M.W.Straight; "too yellow to stand and fight"
turn yellow; "The pages of the book began to yellow"
yellow color or pigment; the chromatic color resembling the hue of sunflowers or ripe lemons (同)yellowness
changed to a yellowish color by age; "yellowed parchment" (同)yellowed
of the color intermediate between green and orange in the color spectrum; of something resembling the color of an egg yolk (同)yellowish, xanthous
a rise in the temperature of the body; frequently a symptom of infection (同)febrility, febricity, pyrexia, feverishness
intense nervous anticipation; "in a fever of resentment"
utter or declare in a very loud voice; "You dont have to yell--I can hear you just fine" (同)scream
highly excited; "a fevered imagination"
the scar left following inoculation with a vaccine

PrepTutorEJDIC

『黄色の』 / 皮膚の黄色い / 《俗》おく病な(cowardly) / (新聞が)センセーショナルな,扇情的な / 〈U〉『黄色』 / 〈C〉黄色いもの;卵黄 / 〈U〉〈C〉黄色の絵の具(顔料,染料),黄色の服 / …‘を'黄色にする / 黄色になる
〈U〉《しばしばa fever》(身体の異常な)『熱』,発熱 / 〈U〉『熱病』 / 〈U〉〈C〉(…に対する)『興奮』,熱狂《+『for』+『名』》
(…を求めて)『大声で叫ぶ』《+for+名》;(…に)大声をあげる《+at+名》 / (…に向かって)…‘を'叫んで(大声で)言う《+out+名(+名+out)+at(to)+名》 / 『叫び声』金切り声,わめき
(比較変化なし)《名詞の前にのみ用いて》熱のある,熱病にかかった / 熱にうかされたような,興奮した / (憎しみなどが)異常に強い
〈C〉〈C〉(…の)種痘,ワクチン接種,予防注射 / 〈C〉種痘の跡

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 黄熱 yellow fever
2. 中央アフリカへの旅行によって感染する可能性のある疾患 diseases potentially acquired by travel to central africa
3. 旅行者のための予防接種 immunizations for travel
4. 妊娠中の予防接種 immunizations during pregnancy
5. HIV感染患者における予防接種 immunizations in hiv infected patients

English Journal

[YEL-AND meningoencephalitis in a 4-year-old boy consecutive to a yellow-fever vaccine.]

Gerin M1, Wroblewski I2, Bost-Bru C3, N'guyen MA3, Debillon T2.Author information 1Clinique universitaire de pédiatrie, hôpital couple-enfant, 38000 Grenoble, France. Electronic address: mgerin@chu-grenoble.fr.2Clinique universitaire de réanimation pédiatrique et médecine néonatale, hôpital couple-enfant, 38000 Grenoble, France.3Clinique universitaire de pédiatrie, hôpital couple-enfant, 38000 Grenoble, France.AbstractYellow fever is a vector-borne disease transmitted by an endemic mosquito in sub-Saharan Africa and tropical South America. It causes fever and possibly liver and renal failure with hemorrhagic signs, which may be fatal. The yellow-fever vaccine is an attenuated vaccine that is recommended for all travelers over the age of 9 months in high-risk areas. Adverse effects have been reported: minor symptoms (such as viral syndrome), hypersensitivity reactions, and major symptoms such as viscerotropic disease (YEL-AVD) and neurotropic disease (YEL-AND). The yellow-fever vaccine-associated autoimmune disease with central nervous system involvement (such as acute disseminated encephalomyelitis) associates fever and headaches, neurologic dysfunction, seizures, cerebrospinal fluid (CSF) pleocytosis, and elevated protein, with neuroimaging consistent with multifocal areas of demyelization. The presence of antibodies or virus in CSF, within 1-30 days following vaccination, and the exclusion of other causes is necessary for diagnosis. We describe herein the case of a 4-year-old child who presented with severe encephalitis consecutive to a yellow-fever vaccine, with favorable progression. Diagnosis is based on the chronology of clinical and paraclinical signs and the presence of yellow-fever-specific antibodies in CSF. The treatment consists of symptomatic treatment and immunoglobulin injection.
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.Arch Pediatr.2014 Mar 11. pii: S0929-693X(14)00035-9. doi: 10.1016/j.arcped.2014.01.014. [Epub ahead of print]
Yellow fever is a vector-borne disease transmitted by an endemic mosquito in sub-Saharan Africa and tropical South America. It causes fever and possibly liver and renal failure with hemorrhagic signs, which may be fatal. The yellow-fever vaccine is an attenuated vaccine that is recommended for all t
PMID 24630625

Prevalence of MERS-CoV nasal carriage and compliance with the Saudi health recommendations among pilgrims attending the 2013 Hajj.

Memish ZA1, Assiri A, Almasri M, Alhakeem RF, Turkestani A, Al Rabeeah AA, Al-Tawfiq JA, Alzahrani A, Azhar E, Makhdoom HQ, Hajomar WH, Alshingiti A, Yezli S.Author information 1Global Centre for Mass Gatherings Medicine (GCMGM), Ministry of Health, Riyadh, Kingdom of Saudi Arabia (KSA)& College of Medicine, Alfaisal University, Riyadh, KSA.AbstractBackground. Saudi Arabia is annually the host of the Hajj mass gathering. We aimed to determine the MERS-CoV nasal carriage rate among pilgrims performing the 2013 Hajj and to describe the compliance with the Saudi Ministry of Health (MoH) vaccine recommendations.Method. Nasopharyngeal samples were collected from 5235 adult pilgrims from 22 countries and screened for MERS-CoV using RT-PCR. Information regarding the participants' age, gender, country of origin, medical conditions as well as vaccination history were obtained.Results. The mean age of the screened population was 51.8 years (range: 18-93 years) with a male/female ratio of 1.17:1. MERS-CoV was not detected in any of the samples tested (3210 pre-Hajj and 2025 post-Hajj screening). According to the vaccination documents, all participants had received meningococcal vaccination and the majority of those from at risk countries were vaccinated against yellow fever and polio. Only 22% of the pilgrims, 17.5% of those ≥65 years and 36.3% of diabetics, had flu vaccination and 4.4% had pneumococcal vaccination.Conclusion. There was no evidence of MERS-CoV nasal carriage among Hajj pilgrims. While rates of compulsory vaccinations uptake were high, uptake of pneumococcal and flu seasonal vaccinations were low including amongst the high risk population.
The Journal of infectious diseases.J Infect Dis.2014 Mar 11. [Epub ahead of print]
Background. Saudi Arabia is annually the host of the Hajj mass gathering. We aimed to determine the MERS-CoV nasal carriage rate among pilgrims performing the 2013 Hajj and to describe the compliance with the Saudi Ministry of Health (MoH) vaccine recommendations.Method. Nasopharyngeal samples w
PMID 24620019

Development of a membrane adsorber based capture step for the purification of yellow fever virus.

Pato TP1, Souza MC2, Silva AN2, Pereira RC2, Silva MV2, Caride E2, Gaspar LP2, Freire MS2, Castilho LR3.Author information 1Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900 Rio de Janeiro/RJ, Brazil; Federal University of Rio de Janeiro, IQ, Biochemistry Program, Av. Athos da Silveira Ramos 149, Bloco A, 21941-909 Rio de Janeiro/RJ, Brazil.2Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900 Rio de Janeiro/RJ, Brazil.3Federal University of Rio de Janeiro, COPPE, Cell Culture Engineering Laboratory, Cx. Postal 68502, 21941-972 Rio de Janeiro/RJ, Brazil; Federal University of Rio de Janeiro, IQ, Biochemistry Program, Av. Athos da Silveira Ramos 149, Bloco A, 21941-909 Rio de Janeiro/RJ, Brazil. Electronic address: leda@peq.coppe.ufrj.br.AbstractYellow fever (YF) is an endemic disease in some tropical areas of South America and Africa that presents lethality rate between 20 and 50%. There is no specific treatment and to control this disease a highly effective live-attenuated egg based vaccine is widely used for travelers and residents of areas where YF is endemic. However, recent reports of rare, sometimes fatal, adverse events post-vaccination have raised concerns. In order to increase safety records, alternative strategies should be considered, such as developing a new inactivated vaccine using a cell culture based technology, capable of meeting the demands in cases of epidemic. With this goal, the production of YF virus in Vero cells grown on microcarriers and its subsequent purification by chromatographic techniques was studied. In this work we investigate the capture step of the purification process of the YF virus. At first, virus stability was studied over a wide pH range, showing best results for the alkaline region. Considering this result and the pI of the envelope protein previously determined in silico, a strong anion exchanger was considered most suitable. Due to the easy scalability, simplicity to handle, absence of diffusional limitations and suitability for virus handling of membrane adsorbers, a Q membrane was evaluated. The amount of antigen adsorbed onto the membrane was investigated within the pH range for virus stability, and the best pH for virus adsorption was considered to be 8.5. Finally, studies on gradient and step elution allowed to determine the most adequate salt concentration for washing (0.15M) and virus elution (0.30M). Under these operating conditions, it was shown that this capture step is quite efficient, showing high product recovery (93.2±30.3%) and efficient DNA clearance (0.9±0.3ng/dose).
Vaccine.Vaccine.2014 Mar 11. pii: S0264-410X(14)00209-6. doi: 10.1016/j.vaccine.2014.02.036. [Epub ahead of print]
Yellow fever (YF) is an endemic disease in some tropical areas of South America and Africa that presents lethality rate between 20 and 50%. There is no specific treatment and to control this disease a highly effective live-attenuated egg based vaccine is widely used for travelers and residents of ar
PMID 24631080